MedPageToday -- Among patients with non-dialysis chronic kidney disease, type 2 diabetes, and anemia who were receiving darbepoetin alfa (Aranesp), those who had a poor initial response to the drug had an increased risk of adverse cardiovascular outcomes and death, researchers found.
